AIM: Continued surveillance of drug resistance amongst children presenting with culture-confirmed tuberculosis to a tertiary care hospital and to community clinics. METHODS: Drug susceptibility testing for isoniazid and rifampicin was prospectively done on all children presenting with culture-confirmed tuberculosis from three study populations: children diagnosed at Tygerberg Children's Hospital in the Western Cape Province, South Africa, between March 2003 and February 2005 (recent survey, hospital-based group), and August 1994 and April 1998 (previous hospital-based survey), and a community-based group from five clinics during the recent survey. RESULTS: Isoniazid resistance increased significantly from 6.9% (21/306 children) in the previous survey to 12.8% (40/313 children) in the recent survey (odds ratio (OR) 1.99, 95% confidence interval (CI) 1.11-3.59). Resistance to isoniazid and rifampicin (multidrug resistance) did not increase significantly between the surveys (7/306 in previous survey vs 17/313 in recent survey; OR 2.45, 95% CI 0.94-6.62). All resistance (isoniazid and/or rifampicin) was 18/127 (14.2%) in the community-based group compared to 23/192 (12.0%) in the hospital-based group (OR 0.82, 95% CI 0.41-1.68). CONCLUSION: The prevalence of drug-resistant tuberculosis in this setting is increasing, reflecting ongoing transmission of drug-resistant Mycobacterium tuberculosis.
AIM: Continued surveillance of drug resistance amongst children presenting with culture-confirmed tuberculosis to a tertiary care hospital and to community clinics. METHODS: Drug susceptibility testing for isoniazid and rifampicin was prospectively done on all children presenting with culture-confirmed tuberculosis from three study populations: children diagnosed at Tygerberg Children's Hospital in the Western Cape Province, South Africa, between March 2003 and February 2005 (recent survey, hospital-based group), and August 1994 and April 1998 (previous hospital-based survey), and a community-based group from five clinics during the recent survey. RESULTS:Isoniazid resistance increased significantly from 6.9% (21/306 children) in the previous survey to 12.8% (40/313 children) in the recent survey (odds ratio (OR) 1.99, 95% confidence interval (CI) 1.11-3.59). Resistance to isoniazid and rifampicin (multidrug resistance) did not increase significantly between the surveys (7/306 in previous survey vs 17/313 in recent survey; OR 2.45, 95% CI 0.94-6.62). All resistance (isoniazid and/or rifampicin) was 18/127 (14.2%) in the community-based group compared to 23/192 (12.0%) in the hospital-based group (OR 0.82, 95% CI 0.41-1.68). CONCLUSION: The prevalence of drug-resistant tuberculosis in this setting is increasing, reflecting ongoing transmission of drug-resistant Mycobacterium tuberculosis.
Authors: Ben J Marais; Tommie C Victor; Anneke C Hesseling; Madeleine Barnard; Annemie Jordaan; Wendy Brittle; Helmuth Reuter; Nulda Beyers; Paul D van Helden; Rob M Warren; H Simon Schaaf Journal: J Clin Microbiol Date: 2006-08-23 Impact factor: 5.948
Authors: A Dramowski; M M Morsheimer; A M Jordaan; T C Victor; P R Donald; H S Schaaf Journal: Int J Tuberc Lung Dis Date: 2012-01 Impact factor: 2.373
Authors: A C Hesseling; S Kim; S Madhi; S Nachman; H S Schaaf; A Violari; T C Victor; G McSherry; C Mitchell; M F Cotton Journal: Int J Tuberc Lung Dis Date: 2012-02 Impact factor: 2.373
Authors: Eric W Hall; Sapna B Morris; Brittany K Moore; Linda Erasmus; Ronel Odendaal; Heather Menzies; Martie van der Walt; Sarah E Smith Journal: Pediatr Infect Dis J Date: 2017-12 Impact factor: 2.129
Authors: Saskia den Boon; Schalk W P van Lill; Martien W Borgdorff; Donald A Enarson; Suzanne Verver; Eric D Bateman; Elvis Irusen; Carl J Lombard; Neil W White; Christine de Villiers; Nulda Beyers Journal: Emerg Infect Dis Date: 2007-08 Impact factor: 6.883